Sphera Funds Management’s Pliant Therapeutics PLRX Stock Holding History

Sphera Funds Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-297,362	Closed	-$3.92M	–	125
2024 Q4	$3.92M	Hold	297,362	–	–	0.71%	51
2024 Q3	$3.33M	Buy	297,362 +38,808	+15%	+$486K	0.53%	55
2024 Q2	$2.78M	Hold	258,554	–	–	0.38%	72
2024 Q1	$3.85M	Buy	258,554 +65,000	+34%	+$1.07M	0.54%	59
2023 Q4	$3.51M	Buy	193,554 +37,420	+24%	+$569K	0.56%	62
2023 Q3	$2.71M	Buy	+156,134	New	+$2.71M	0.49%	61
2021 Q3	–	Sell	-51,000	Closed	-$1.49M	–	142
2021 Q2	$1.49M	Buy	+51,000	New	+$1.59M	0.1%	112

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Sphera Funds Management's PLRX Position: Q1 2025 in Review

Sphera Funds Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 297,362 shares — an estimated $3.92M sold.

Sphera Funds Management first reported a position in PLRX in Q2 2021 and held it in 7 quarters. The position peaked at $3.92M in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

Sphera Funds Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
Sphera Funds Management sold 297,362 Pliant Therapeutics shares in Q1 2025, an estimated $3.92M.
Sphera Funds Management first reported a position in Pliant Therapeutics in Q2 2021 and held it in 7 quarters.
Sphera Funds Management's Pliant Therapeutics position peaked at $3.92M in Q4 2024.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Sphera Funds Management's 13F filing for Q1 2025, filed 15 May 2025.